Sachdeva Kabir, Upadhyay Divyesh, Discutido Richard, Varghese Merlin Mary, Albuz Firas, Almekosh Rawan, Bouhafs Linda, Solkar Sadika, Stevikova Martina, Peramo Braulio
Genetics Department, Al Ain Fertility Center , Al Ain, Al Jimi, United Arab Emirates .
Genet Test Mol Biomarkers. 2018 Oct;22(10):630-634. doi: 10.1089/gtmb.2018.0063. Epub 2018 Sep 7.
Retrospective analysis of embryo aneuploidy in patients undergoing in vitro fertilization (IVF) cycles.
To evaluate factors that might affect the incidence of embryo aneuploidy during IVF cycles.
Three hundred twelve IVF cases were included in the present study. Preimplantation genetic testing for aneuploidy (PGT-A) was performed for all the subjects involved. Subject stratification was done based on maternal age, gonadotropin drug dosage, and IVF outcomes data. Maternal age <35 years were placed in the "Young" age group and age ≥35 years were placed in the "Advanced Maternal Age" group. Similarly, IVF drug administered <200 International units (IU) was considered "low dosage," group and ≥200 IU were considered "high dosage" group. Patients were stratified into four groups-group 1: age <35 years and administered <200 IU; group 2: age <35 years and administered ≥200 IU; group 3: age ≥35 years and administered at <200 IU; and group 4: age ≥35 years and administered ≥200 IU. PGT-A results were attained using a next-generation sequencing-based protocol. Embryo transfer was guided by transabdominal ultrasound. Statistical significance was calculated with the use of chi-square test.
One thousand fifty blastocyst trophectoderm biopsies from 312 IVF cases were retrieved. The IVF outcome of a total of 105 normal cases resulted in 65.71% pregnancies. Stratifying for maternal age and IVF drug stimulation with PGT-A analyses we found the euploid embryo percentages equal to 37.59% in Group 1; 16.18% in Group 2; 22.44% in Group 3; and 2.59% in Group 4. Similarly the aneuploid embryo (percentage)s were 62.40% for Group 1; 83.81% for Group 2; 77.55% for Group 3; and 87.40% for Group 4.
This is the first clinical study reporting that gonadotropin dosage may act as a contributing factor in increasing aneuploidy incidences for the patients undergoing IVF cycles in the UAE population. This study shows that in all patient age groups, lower drug stimulation leads to an increasing trend in embryo euploidy.
对接受体外受精(IVF)周期的患者胚胎非整倍体的回顾性分析。
评估可能影响IVF周期中胚胎非整倍体发生率的因素。
本研究纳入312例IVF病例。对所有参与研究的对象进行植入前非整倍体基因检测(PGT-A)。根据产妇年龄、促性腺激素药物剂量和IVF结局数据进行受试者分层。产妇年龄<35岁的被归入“年轻”年龄组,年龄≥35岁的被归入“高龄产妇”组。同样,IVF药物用量<200国际单位(IU)的被视为“低剂量”组,≥200 IU的被视为“高剂量”组。患者被分为四组——第1组:年龄<35岁且用药量<200 IU;第2组:年龄<35岁且用药量≥200 IU;第3组:年龄≥35岁且用药量<200 IU;第4组:年龄≥35岁且用药量≥200 IU。PGT-A结果通过基于新一代测序的方案获得。胚胎移植由经腹超声引导。使用卡方检验计算统计学意义。
从312例IVF病例中获取了1050次囊胚滋养外胚层活检样本。总共105例正常病例的IVF结局导致妊娠率为65.71%。通过PGT-A分析按产妇年龄和IVF药物刺激进行分层,我们发现第1组的整倍体胚胎百分比为37.59%;第2组为16.18%;第3组为22.44%;第4组为2.59%。同样,第1组的非整倍体胚胎(百分比)为62.40%;第2组为83.81%;第3组为77.55%;第4组为87.40%。
这是第一项临床研究报告,表明促性腺激素剂量可能是阿联酋人群中接受IVF周期的患者非整倍体发生率增加的一个促成因素。本研究表明,在所有患者年龄组中,较低的药物刺激会导致胚胎整倍体呈上升趋势。